JPS6151568B2 - - Google Patents
Info
- Publication number
- JPS6151568B2 JPS6151568B2 JP11646278A JP11646278A JPS6151568B2 JP S6151568 B2 JPS6151568 B2 JP S6151568B2 JP 11646278 A JP11646278 A JP 11646278A JP 11646278 A JP11646278 A JP 11646278A JP S6151568 B2 JPS6151568 B2 JP S6151568B2
- Authority
- JP
- Japan
- Prior art keywords
- histamine
- diluteiazem
- cimetidine
- peptic ulcers
- acid addition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 150000007657 benzothiazepines Chemical class 0.000 claims description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 16
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 9
- 229960001380 cimetidine Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229960001340 histamine Drugs 0.000 description 8
- 239000012266 salt solution Substances 0.000 description 4
- 210000002837 heart atrium Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000002057 chronotropic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 210000005247 right atrial appendage Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11646278A JPS5543036A (en) | 1978-09-20 | 1978-09-20 | Medical composition containing histamine h22 acceptor antagonist |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11646278A JPS5543036A (en) | 1978-09-20 | 1978-09-20 | Medical composition containing histamine h22 acceptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5543036A JPS5543036A (en) | 1980-03-26 |
| JPS6151568B2 true JPS6151568B2 (cs) | 1986-11-10 |
Family
ID=14687702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11646278A Granted JPS5543036A (en) | 1978-09-20 | 1978-09-20 | Medical composition containing histamine h22 acceptor antagonist |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5543036A (cs) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6010074B2 (ja) * | 1982-08-13 | 1985-03-14 | 日本油脂株式会社 | 分散燃料組成物 |
-
1978
- 1978-09-20 JP JP11646278A patent/JPS5543036A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5543036A (en) | 1980-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2311498T3 (es) | Composiciones medicinales que contienen aspirina. | |
| PT1437131E (pt) | Utilização de ramipril para a prevenção de diabetes num doente sem insuficiência cardíaca congestiva pré-existente | |
| JPH07501547A (ja) | 光学的に純粋な（−）アムロジピンを用いる，高血圧，狭心症および他の疾患を治療するための方法および組成物 | |
| US5028628A (en) | Methods of treating pulmonary hypertension | |
| JPH01100120A (ja) | 薬剤組成物 | |
| PT97477B (pt) | Processo de preparacao de composicoes farmaceuticas a base de antagonistas dos receptores 5-ht4 | |
| JP2002255814A (ja) | アスピリンを含有する医薬組成物 | |
| JP2810426B2 (ja) | 虚血治療用組成物 | |
| EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
| JPS6151568B2 (cs) | ||
| CZ298745B6 (cs) | Farmaceutická kombinace, farmaceutický přípravek, způsob jeho výroby a použití kombinace | |
| CN113786405B (zh) | 四氢小檗红碱在制备心脏保护药物中的用途 | |
| JP2665357B2 (ja) | 心不全治療用医薬組成物 | |
| KR100260479B1 (ko) | 혈압강하용 복합제제 | |
| US4175128A (en) | Method for treating congestive heart failure | |
| JP2710633B2 (ja) | 心臓疾患治療剤 | |
| PL184904B1 (pl) | Zastosowanie związków 3-benzoilo-3Ć7-diazabicyklo-[3Ć3Ć1] nonanu do wytwarzania leku do leczenia zakłóceń rytmu serca | |
| WO1986006960A2 (en) | Use of nicorandil or pinacidil for the treatment of peripheral vascular disease | |
| CZ20014685A3 (cs) | Lék pro léčbu nebo prevenci vazospazmu koronárního ątěpu | |
| CA1229793A (en) | Medicament for cerebral apoplexy | |
| US3821381A (en) | Method of treatment | |
| JP2834507B2 (ja) | 芳香族誘導体を活性成分とする疾患治療剤 | |
| KR920003580B1 (ko) | 동맥경화증 예방 및 치료제 | |
| JPH02262519A (ja) | 糖尿病性神経障害治療剤 | |
| JPH0647540B2 (ja) | 虚血性心疾患・不整脈治療・予防剤 |